Desvenlafaxine succinate is a serotonin-norepinephrine reuptake inhibitor (SNRI) and the major active metabolite of venlafaxine. It is indicated for the treatment of Major Depressive Disorder (MDD). It works by increasing the levels of serotonin and norepinephrine, two neurotransmitters in the brain that are known to regulate mood. In the Indian context, it is a widely prescribed antidepressant with a favorable tolerability profile for many patients.
Adult: Recommended starting and therapeutic dose is 50 mg once daily, with or without food. Dose can be increased to 100 mg/day based on clinical response and tolerability.
Note: Tablet should be swallowed whole with water, preferably at the same time each day. Do not crush, chew, or dissolve. Can be taken with or without food.
Desvenlafaxine is a potent and selective inhibitor of neuronal serotonin (5-HT) and norepinephrine (NE) reuptake. It does not significantly inhibit the reuptake of dopamine or have high affinity for muscarinic-cholinergic, H1-histaminergic, or alpha1-adrenergic receptors.
Pregnancy: Pregnancy Category C (US FDA). Data in humans is limited. Potential risks include neonatal adaptation syndrome (respiratory distress, feeding difficulty, hypotonia, irritability) if used in the third trimester. Use only if potential benefit justifies potential risk to the fetus. Consider tapering in the third trimester if clinically feasible.
Driving: May impair ability to drive or operate machinery, especially during initial therapy or dose changes. Patients should be cautioned until they are reasonably certain the drug does not affect them adversely.
| Monoamine Oxidase Inhibitors (MAOIs) - e.g., Phenelzine, Selegiline, Linezolid | Risk of potentially fatal serotonin syndrome, hyperthermia, rigidity, myoclonus. | Contraindicated |
| Other Serotonergic Drugs (SSRIs, SNRIs, TCAs, Triptans, Tramadol, Fentanyl, Lithium, St. John's Wort) | Increased risk of serotonin syndrome. | Major |
| NSAIDs, Aspirin, Warfarin, Clopidogrel | Increased risk of bleeding due to effect on platelet serotonin. | Moderate |
| Drugs that Prolong QTc Interval (e.g., Class IA/III antiarrhythmics, certain antipsychotics, antibiotics) | Potential additive effect on QTc prolongation. | Moderate |
| CYP3A4 Inhibitors (e.g., Ketoconazole) | May increase desvenlafaxine plasma concentrations. | Minor |